Recently, AXL-targeting therapies may be beneficial for NSCLC patients bearing wild-type EGFR tumors with mesenchymal features and frequent KRAS mutations, and those harboring EGFR-activating mutations with resistance to EGFR inhibitors [23]. Here, AXL is linked to non-small cell lung carcinoma.